Single-centre retrospective review of dupilumab-induced ocular surface disease in an Australian adult cohort with moderate-to-severe atopic dermatitis

被引：0

作者：

Arasu, Alexis ^{[1
]}

Awad, Andrew ^{[1
]}

Tran, Vanessa ^{[1
]}

Ross, Gayle ^{[1
,2
]}

机构：

[1] Royal Melbourne Hosp, Dermatol Dept, Parkville, Vic, Australia

[2] Univ Melbourne, Parkville, Vic, Australia

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2025年 / 66卷 / 01期

关键词：

atopic dermatitis; dupilumab; ocular surface disease;

D O I：

10.1111/ajd.14400

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.

引用

页码：e24 / e27

页数：4

共 12 条

[1]

Foley P., Kerdraon Y.A., Hogden J.P., Shumack S., Spelman L., Sebaratnam D.F., Et al., Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting, Australas J Dermatol, 63, 4, pp. 421-436, (2022)

[2]

Halling A.S., Loft N., Silverberg J.I., Guttman-Yassky E., Thyssen J.P., Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis, J Am Acad Dermatol, 84, 1, pp. 139-147, (2021)

[3]

Akinlade B., Guttman-Yassky E., de Bruin-Weller M., Simpson E.L., Blauvelt A., Cork M.J., Et al., Conjunctivitis in dupilumab clinical trials, Br J Dermatol, 181, 3, pp. 459-473, (2019)

[4]

Pietruszynska M., Zawadzka-Krajewska A., Duda P., Rogowska M., Grabska-Liberek I., Kulus M., Ophthalmic manifestations of atopic dermatitis, Adv Dermatol Allergol Dermatol Alergol, 37, 2, pp. 174-179, (2020)

[5]

Blauvelt A., de Bruin-Weller M., Gooderham M., Cather J.C., Weisman J., Pariser D., Et al., Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial, Lancet Lond Engl, 389, 10086, pp. 2287-2303, (2017)

[6]

Neagu N., Dianzani C., Avallone G., Dell'Aquila C., Morariu S.H., Zalaudek I., Et al., Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review, J Eur Acad Dermatol Venereol, 36, 6, pp. 820-835, (2022)

[7]

Thyssen J.P., de Bruin-Weller M.S., Paller A.S., Leshem Y.A., Vestergaard C., Deleuran M., Et al., Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion, J Eur Acad Dermatol Venereol, 33, 7, pp. 1224-1231, (2019)

[8]

Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience – PubMed [Internet]

[9]

Touhouche A.T., Cassagne M., Berard E., Giordano-Labadie F., Didier A., Fournie P., Et al., Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study, J Eur Acad Dermatol Venereol JEADV, 35, 1, pp. 172-179, (2021)

[10]

Guttman-Yassky E., Blauvelt A., Eichenfield L.F., Paller A.S., Armstrong A.W., Drew J., Et al., Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial, JAMA Dermatol, 156, 4, pp. 411-420, (2020)

← 1 2 →